Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

Gastroenterology

Volumn 119, Issue 3, 2000, Pages 670-676

  Sagar, Mohamed ^a   Tybring, Gunnel ^b   Dahl, Marja Liisa ^b   Bertilsson, Leif ^b   Seensalu, Rein ^a,c  

^a Clinical Research Center   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; ENZYME POLYMORPHISM; FEMALE; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; GENOTYPE; HELICOBACTER PYLORI; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

EID: 0033851533     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.16515     Document Type: Article

References (43)

1. Pharmacokinetics and metabolism of omeprazole in man
2. Omeprazole: Pharmacokinetics and metabolism in man
3. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
4. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from Oriental population
5. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
6. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
7. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
8. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid related disorders with and without H. pylori infection
9. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population
10. Pronounced differences between native Chinese and Swedish populations in the polymorphic bydroxylations of debrisoquin and S-mephenytoin
11. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese population
12. Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability of omeprazole as a probe for CYP2C19
13. Effects of Helicobacter pylori status on intragastric pH during treatment with omeprazole
14. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole
15. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori-associated gastritis
16. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
17. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease
18. Mononuclear cells and cytokines stimulate gastrin release from canine antral cells in primary culture
19. H. pylori stimulates gastrin release from canine antral cells in primary culture
20. Helicobacter pylori infection causes hypergastrinaemia during omeprazole therapy
21. Increased plasma gastrin levels in connection with inhibition of gastric acid responses to sham feeding following bulbar perfusion with acid in dogs
22. Helicobacter pylori in 205 consecutive endoscopy patients
23. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age
24. Effect of omeprazole - A gastric proton pump inhibitor - On pentagastrin stimulated acid secretion in man
25. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects
26. The effect of 20 mg omeprazole daily on serum gastrin, 24-h intragastric acidity, and bile acids concentration in duodenal ulcer patients
27. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity
28. Variability in individual response to various doses of omeprazole, implications for antiulcer therapy
29. Long-term omeprazole treatment in man: Effects on gastric endocrine cell populations
30. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
31. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
32. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer
33. Helicobacter pylori augments the pH-increasing effect of omeprazole in the patients with duodenal ulcer
34. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
35. The treatment of Helicobacter pylori infection
36. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantaprazole
37. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion
38. Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine
39. Gastric mucosa during treatment with lanzoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
40. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lanzoprazole
41. Lanzoprazole, H. pylori, and atrophic gastritis
42. Lack of effect of acid suppression therapy on gastric atrophy
43. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication